Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is a promising biotechnology company with a selective tyrosine kinase inhibitor that targets the underlying cause of Systemic Mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST). However, there are risks to the attainment of our rating and price target, including potential downward adjustments in market penetration due to poor clinical results, emergence of better-than-expected competitor products, and regulatory/commercial risks. These may result in a longer horizon to approval or preclusion of approval, as well as a change in fair value of their Contingent Value Right liability.

Bears say

Cogent Biosciences is expected to experience increased revenues in the near future due to potential FDA approvals for its precision therapies, specifically bezuclastinib, in multiple indications such as systemic mastocytosis and gastrointestinal stromal tumors. Despite a strong balance sheet and potential for future growth, the company remains a high-risk investment due to the uncertain success of its pipeline and potential competition from other companies. Additionally, the negative earnings reported in the recent quarter and projected losses for the full year may also be cause for concern for potential investors.

COGT has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 10 analysts, COGT has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.